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In clinical practice, reducing the burden of persistent atrial fibrillation by pharmacological 
means is challenging. We explored if blocking the background and the acetylcholine-
activated inward rectifier potassium currents (IK1 and IKACh) could be antiarrhythmic in 
persistent atrial fibrillation. We thus tested the hypothesis that blocking IK1 and IKACh with 
chloroquine decreases the burden of persistent atrial fibrillation. We used patch clamp to 
determine the IC50 of IK1 and IKACh block by chloroquine and molecular modeling to simulate 
the interaction between chloroquine and Kir2.1 and Kir3.1, the molecular correlates of IK1 
and IKACh. We then tested, as a proof of concept, if oral chloroquine administration to 
a patient with persistent atrial fibrillation can decrease the arrhythmia burden. We also 
simulated the effects of chloroquine in a 3D model of human atria with persistent atrial 
fibrillation. In patch clamp the IC50 of IK1 block by chloroquine was similar to that of IKACh. 
A 14-day regimen of oral chloroquine significantly decreased the burden of persistent 
atrial fibrillation in a patient. Mathematical simulations of persistent atrial fibrillation in a 3D 
model of human atria suggested that chloroquine prolonged the action potential duration, 
leading to failure of reentrant excitation, and the subsequent termination of the arrhythmia. 
The combined block of IK1 and IKACh can be a targeted therapeutic strategy for persistent 
atrial fibrillation.
Keywords: chloroquine, persistent atrial fibrillation, potassium inward rectifiers, IKACh, IK1
INTRODUCTION
Atrial fibrillation (AF) is the most common heart rhythm abnormality and its incidence and 
prevalence are increasingly alarming. In addition to increasing mortality, AF is a known risk factor 
for stroke (Wolf et al., 1991), dementia (Liao et al., 2015; Singh-Manoux et al., 2017), and cardiac 
contractile dysfunction (Schotten et al., 2002). Pharmacological rhythm control therapy for AF 
remains attractive, however, when AF becomes persistent, pharmacotherapy is frequently ineffective 
(Zimetbaum, 2012).
Chloroquine, an antimalarial 4-aminoquinoline, has been suggested to have antiarrhythmic 
properties through unknown mechanisms (Burrell and Martinez, 1958; Harris et al., 1988), and 
was shown to have a safe cardiac electrophysiological profile (Wozniacka et al., 2006; Teixeira et al., 
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2014). Our previous work suggested that chloroquine terminates 
different forms of AF in animal models, in part, due to its ability 
to block potassium inward rectifiers (Noujaim et al., 2010; 
Filgueiras-Rama et al., 2012; Takemoto et al., 2018).
In persistent AF, the acetylcholine-activated inward rectifier 
potassium current IKACh (molecular correlates are Kir3.1 and 
Kir3.4) was shown to be constitutively active and the inward 
rectifier potassium current IK1 (molecular correlates Kir2.1 and 
Kir2.3) has been shown to be upregulated (Voigt et al., 2010; 
Dobrev and Nattel, 2011). The constitutively active IKACh could 
be considered as a background inward rectifier, which along with 
the increased IK1 may contribute to the shortening of the action 
potential duration and to create a substrate for the formation of 
stable, high frequency electrical rotors that maintain fibrillation 
(Atienza and Jalife, 2007; Noujaim et al., 2007). Consequently, 
blocking inward rectifiers could potentially be antiarrhythmic in 
the setting of persistent AF.
Recently, we used structural biology approaches to map the 
binding pocket of chloroquine in the intracellular domain of 
Kir3.1 (Takemoto et al., 2018). Chloroquine blocked IKACh by 
binding at a specific site in the Kir3.1 intracellular ion permeation 
pathway (Takemoto et al., 2018). Previous work by us and others 
showed that chloroquine also blocks Ik1 (Rodriguez-Menchaca 
et al., 2008; Noujaim et al., 2010). In this study, we tested in a 
patient with persistent AF whether chloroquine can reduce the 
arrhythmia burden, and we further explored the antiarrhythmic 




Experiments were performed as described earlier (Noujaim et al., 
2011; Takemoto et al., 2018). HEK293 cells stably co-transfected 
with Kir3.1 and Kir3.4 were generously provided by the Bayliss 
Laboratory (University of Virginia), and HEK293 cells stably 
transfected with Kir2.1 were generously provided by the Jalife 
Laboratory (University of Michigan). Currents were recorded 
using EPC 800 amplifier (HEKA Elektronik, Lambrecht/Pfalz), 
A/D converter (Digidata 1550B plus Hum Silencer, Molecular 
Devices, San Jose, CA), and the pClamp 10.6 PC software 
(Molecular Devices). Analysis was performed with Clampfit 10.6 
(pClamp, Molecular Devices) and OriginPro software packages 
(version 2018, Microcal). The patch pipettes had a resistance of 
2.5–3MΩ. After GΩ seal formation, whole cell recordings were 
performed at room temperature (around 24°C). For IKACh, the 
bath solution contained (in mM) 90 NaCl, 50 KCl, 1 CaCl2, 2 
MgCl2, 10 HEPES, 10 glucose, and the pH adjusted to 7.4. The 
pipette internal solution contained (in mM) 100 K-aspartate, 10 
NaCl, 40 KCl, 5 Mg-ATP, 2 EGTA, 0.1 GTP-Tris, and 10 HEPES 
at pH 7.2. For IK1, the bath solution contained (in mM) 148 
NaCl, 0.4 NaH2PO4, 1 MgCl2, 5.4 KCl, 1.8 CaCl2, 5.5 glucose, 15 
HEPES, pH 7.4, and the pipette internal solution contained (in 
mM), 150 KCl, 1 MgCl2, 5 EGTA, 5 HEPES, 5 phosphocreatine, 
4.4 K2ATP, and pH 7.2. IKACh and IK1 were measured as the 1mM 
BaCl2 sensitive current. Concentration–response curves and IC50 
for currents inhibition at −140mV were determined with Prism 
7 software using the standard variable slope equation Y = 1/(1 + 
10(LogIC50 − X)*Slope).
Molecular Docking of Chloroquine Into 
Kir2.1 and Kir3.1
As we previously described, the intracellular domain of tetrameric 
Kir2.1 (PDB: 1U4F) (Pegan et al., 2005) and Kir3.1 (PDB: 1U4E) 
(Pegan et al., 2005) were used for the docking simulations. The 
SMILES string for chloroquine was obtained from Drugbank 
(Wishart et al., 2008) (Accession Number: DB00608). The Kir2.1 
and Kir3.1 proteins, and chloroquine were prepared using the 
Protein Preparation Wizard and LigPrep in Schrodinger’s Maestro 
(Sastry et al., 2013), respectively. The protonation state of the drug 
was generated at a target pH of 7.0 in Epik (Shelley et al., 2007; 
Greenwood et al., 2010). The ligand was energy minimized with the 
OPLS_2005 force field (Shivakumar et al., 2010). A set of grids was 
created to map the proteins topologies before docking. The grids 
were generated using 60 × 60 × 60 points in the x, y, and z directions 
and centered around the aqueous channel with a spacing of 0.375 
Å. Docking was performed with the Lamarckian genetic algorithm, 
with the population size set to 150, the number of generations set 
to 27,000 and the number of energy evaluations set to 2,500,000. 
Using Autodock 4.2 (Morris et al., 2009), one thousand runs were 
performed. The lowest energy poses from molecular docking were 
analyzed. Hydrogen bond analysis was performed using Visual 
Molecular Dynamics (Humphrey et al., 1996).
estimation of Blocking Ability of Chloroquine
A voxel grid was generated using the atomic coordinates of the 
lowest energy pose from molecular docking of the tetrameric 
Kir2.1 or Kir3.1 bound to chloroquine. In this grid, each voxel was 
a cube of 0.2 × 0.2 × 0.2 Å. The van der Waals radius of each atom 
(Iijima et al., 1987) was used to fill the corresponding number of 
cubes. The use of the discrete grid allowed for a probe to search 
the space in the aqueous ion-permeation pathway. The probes 
were Voxel-approximated spheres with radii ranging from 1.4 Å 
(the ionic radius of a bare K+ ion) to 3.9 Å in 0.1 Å increments. 
Three ångströms is the radius of a solvated K+ ion up to its first 
hydration shell (Mahler and Persson, 2012). Originating from 
the extracellular opening of the channel, the probes were pushed 
longitudinally through the channel towards the intracellular 
side. If, at any point in the pathway, the probe was unable to 
proceed further, the probe’s lateral position was adjusted in order 
to search all possible paths through the channel. The channel 
was considered blocked at a given probe radius if the probe was 
unable to find a path to move past chloroquine.
human study
A 67 year old female with history of tobacco use, persistent AF 
(AF sustained for more than seven days, and less than a year), 
and no other significant past medical history including no known 
coronary artery disease, was enrolled in this study. Institutional 
Review Board approval was obtained at the University of 
South Florida, Tampa, USA, and the study conformed to the 
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principles outlined in the Declaration of Helsinki. Prior workup 
revealed normal blood pressure. Her laboratory values showed 
normal kidney and liver function tests. Echocardiography was 
unremarkable for structural heart disease, with an ejection 
fraction >50%. The patient has been on Apixaban and Metoprolol, 
and continued to be on these medications during the study. The 
patient gave informed consent, was equipped with a Cardionet 
monitor, and received the chloroquine regimen for amebiasis 
treatment, consisting of 600 mg chloroquine base once daily for 2 
days, followed by 300 mg daily for 12 days. She was continuously 
monitored for the duration of chloroquine treatment. A previous 
Holter monitor recording (ZIO XT Patch) for 12 days obtained 
two months prior, was reviewed and showed that the patient had 
been continuously in AF, with a burden of 100%. Additionally, 
12 lead ECG was recorded 3 days before and on the day of 
chloroquine regimen initiation, confirming that the patient was 
in AF in both instances.
Mathematical simulations of Persistent 
Atrial Fibrillation in a 3D Model  
of human Atria
The Courtemanche-Ramirez-Nattel membrane formalism 
(Courtemanche et al., 1998) was implemented to simulate the 
human atrial cell action potential. Cholinergic activity, a factor 
that promotes AF, was included in the model by implementing the 
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where Vm is the membrane potential, ACh is the acetylcholine 
concentration and EK is the potassium equilibrium potential.
Based on experimental data (Workman et al., 2001; Van 
Wagoner, 2003), the cell model was modified in order to 
reproduce electrophysiological conditions of persistent AF: 
the maximum conductance of IK1 was increased by 100%, the 
maximum conductance of transient potassium current (Ito) and 
delayed rectifier potassium current (IKur) were decreased by 50%, 
and the maximum conductance of L-type calcium current (ICaL) 
was decreased by 70% and for the constitutively active IKACh, 5 
nM of acetylcholine was simulated.
A realistic three-dimensional (3D) model of human atria 
including the main anatomical structures: left and right atria, 
twenty pectinate muscles, fossa ovalis, Bachmann’s bundle, crista 
terminalis, left and right appendages, pulmonary veins, caval 
veins, atrioventricular rings and coronary sinus, was previously 
developed (Tobon et al., 2013). The model also includes three 
different pathways for the inter-atrial conduction, specific fiber 
orientations in 42 different atrial regions, heterogeneous tissue 
conductivity, anisotropy ratios and heterogeneous cellular 
properties. The wall of the atrial model is a monolayer surface, 
except the Bachmann’s bundle and the pectinate muscles, which 
are solid structures. The model is composed of 52,906 hexahedral 
elements with a spatial resolution ranging from 300 to 700 μm.
The mathematical atrial cell model coupled with the 3D 
model was used to simulate a persistent AF episode. AF was 
generated with an S1–S2 stimulation protocol. S1 consisted of a 
train of ten stimuli with a basic cycle length of 1,000 ms, applied 
to the sinus node area, simulating sinus rhythm. After the last 
S1 stimulus, 6 ectopic S2 beats at 130 ms cycle length were 
delivered to the right superior pulmonary vein. Action potential 
















where, Sv corresponds to the surface-to-volume ratio (range from 
0.0086 to 0.02), D is the conductivity tensor, Cm is the membrane 
capacitance (100 pF), Iion is the total ionic current that crosses the cell 
membrane and Istim is the stimulus current (28 pA/pF). Equations 
were numerically solved using EMOS software (Heidenreich et al., 
2010), which is a parallel code that implements the finite element 
method and operator splitting for solving the monodomain model. 
The time step was fixed to 0.001 ms. Simulation of 2 s of atrial 
activity required 32 h on a computing node with 12 dual core AMD 
Opteron Processors 2,218 clocked at 2.6 GHz.
Pseudo-unipolar atrial electrograms (EGMs) in the 3D model 
at 0.2 mm from the surface were simulated. The extracellular 
potential (Φe) in the endocardial atrial surface was computed 
using the large volume conductor approximation
 
φe mr K V r r r








where K (−0.0398) is a constant that includes the ratio of 
intracellular and extracellular conductivities, ∇ʹVm is the spatial 
gradient of transmembrane potential, r is the distance from the 
source point (x, y, z) to the measuring point (x’, y’, z’) and dv is 
the differential volume. EGMs at different points were visually 
inspected in order to analyze their morphologies as single, double 
or fractionated potentials. Double potentials were defined as 
EGMs with two negative or positive deflections and fractionated 
electrograms were defined as those exhibiting multiple (more 
than two) deflections. EGMs were processed with a 40–250 
Hz band-pass filter, rectified and low-pass filtered at 20 Hz. 
Subsequently, spectral analysis of the signals was performed with 
a fast Fourier transform. The dominant frequency (DF) defined 
as the frequency corresponding to the highest peak of the power 
spectrum was calculated.
Modeling the effect of Chloroquine on 
Potassium Currents
To develop a basic model of the effect of chloroquine on the 
major potassium currents that this drug has been shown to block 
(IKACh, IK1, and IKr) (Sanchez-Chapula et al., 2001), we used the 
steady state fraction of block (f), as done previously (Duarte M 
et al., 2013):
 f IC C= +1 1 50/ ( /[ ])  
where C is the chloroquine concentration. The Hill equation 
was used to fit the Concentration–response relationships for 
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chloroquine block. In this model, the channels kinetics were 
considered unchanged in the presence of the chloroquine. The IC50 
for IKACh and IK1 block by chloroquine were used from Figures 1 
and 2 and our earlier work (Noujaim et al., 2010) (0.97 μM for 
IK1 and 1.0 μM for IKACh). For IKr, we used an IC50 of 2.5 μM as 
reported by Traebert et al in HEK293 cells (Traebert et al., 2004). 
The simulated fraction of block curve for IKACh current fit well 
the experimental data shown in Figures 1 and 2, where (1 − f) · 
100% is the remaining current. After 5 s of baseline AF simulation, 
chloroquine was applied at increasing concentrations, from 1.0 μM 
to 8.7 μM, in order to simulate ~50% to ~90% block of IK1 and IKACh, 
and from 1.0 μM to 25 μM, in order to simulate 30% to 90% block 
of IKr. We investigated the effects of chloroquine on AF dynamics 
by blocking either IK1, IKACh or IKr alone, or by blocking both IK1 and 
IKACh, or by blocking the three currents. Action potential duration 
at 90% repolarization (APD90) and the resting membrane potential 
(RMP) in a left atrial single cell were measured. All simulations 
were halted 2 s after chloroquine application.
ResUlTs
Chloroquine Block of IK1 and IKACh 
Our earlier study using modeling, and protein NMR, suggested 
that chloroquine binds the intracellular domain of Kir3.1, at the 
level of amino acids F255 and D260 (Takemoto et al., 2018). Here, 
we conducted similar molecular docking simulations in order 
to compare the binding of chloroquine to Kir2.1 and Kir3.1. For 
each complex, one thousand docking runs were performed. The 
lowest energy poses for ligand–protein interactions were further 
studied. Figures 1A and 2A, left panels, are zoomed in views of the 
tetrameric Kir2.1 (Figure 1A) and Kir3.1 (Figure 2A) channels, 
represented by gray ribbons, with the docked chloroquine depicted 
in cyan. In Kir2.1 (Figure 1A), the tertiary amine of chloroquine 
hydrogen-bonded to residue E224 of subunit B (black circles), 
and the aminoquinoline ring formed a hydrogen bond with the 
carbonyl oxygen of the diametrically opposed E224 of subunit 
D. The binding energy of chloroquine to Kir2.1 was –6.09 Kcal/
mol. In Kir3.1 (Figure 2A), the tertiary amine of chloroquine 
hydrogen-bonded to residue D260 of subunit B (black circles), 
and the aminoquinoline ring was in proximity to the F255 ring 
of the adjacent subunit A. The binding energy of the ligand to the 
channel was −6.37 Kcal/mol. The Van der Waals representations 
of the Kir2.1 and Kir3.1 in complex with chloroquine are shown 
from the extracellular bird’s eye views (Figures 1A and 2A, bottom 
panels). The ion permeation pathways are in the middle, and the 
white arrows point to chloroquine which is shown in cyan. We then 
used patch clamp to compare the IC50 for chloroquine block of IK1 
(Figure 1B) and IKACh (Figure 2B). Top panels are representative 
FIgURe 1 | IK1 block with chloroquine. (A) Docking of chloroquine in the intracellular domain of Kir2.1. The lowest energy pose is shown. Chloroquine makes hydrogen 
bonds with residue E224 from subunit B and with E224 from subunit D (black circles). Bottom panel: Extracellular bird’s eye views of the van der Waals representation 
of the channel (gray) in complex with chloroquine (cyan). Chloroquine blocks the ion permeation pathway. (B) Barium sensitive IK1 traces in response to −140mV step 
pulses from a holding potential of 0 mV in the presence of 1 μM chloroquine (CQ). Concentration–response curves. IC50 for chloroquine block of IK1: 1.3 μM, Hill Slope = 
−0.42, R2=0.9. (C) Top panel: Longitudinal view of chloroquine bound to Kir2.1. Orange box denotes the voxelated part of the channel shown below. Bottom panel: 
Voxelation of Kir2.1 ion permeation pathway (grey) in complex with chloroquine (cyan). A probe (magenta) of radius 2.1 Å or larger, is blocked by chloroquine.
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current traces in response to voltage steps in the presence of 1 μM 
chloroquine. In the concentration–response curves, the IC50s of 
IK1 and IKACh block by chloroquine at −140 mV were 1.3 μM and 
1.2 μM respectively. Subsequently, we voxelated the models for 
Kir2.1 and Kir3.1 in order to verify that in the docked structures, 
chloroquine is able to block the flow of potassium ions through 
the intracellular ion permeation pathway (Figures 1C and 2C). 
The intracellular domains of Kir2.1 and 3.1 are shown in the 
longitudinal view, with the front subunit removed, and bound 
chloroquine (cyan sticks) is exposed. In Kir2.1, chloroquine 
binds closer to the G loop area, while in Kir3.1, chloroquine binds 
towards the intracellular mouth of the permeation pathway. The 
orange box denotes the voxelated part of the channels presented 
in the bottom panels of Figures 1C and 2C. It was found that in 
Kir2.1, a probe (magenta sphere) of radius ≥2.1 Å was blocked 
by the drug, while probes with radii <2.1 Å passed through. In 
Kir3.1, a probe of radius ≥2.2 Å was blocked by the drug, while 
probes with radii <2.2 Å passed through. 3.0 Å is the radius of 
a solvated K+ ion up to its first hydration shell. These results are 
in agreement with the patch clamp experiments which showed 
similar IC50 for chloroquine block of Kir2.1 and Kir3.1.
Chloroquine Treatment in a Patient With 
Persistent AF
As proof of concept, we tested in a patient with persistent atrial 
fibrillation, whether chloroquine can modify the AF burden. 
This 67 year old female was non-diabetic, non-hypertensive, a 
previous smoker, with no known structural heart or coronary 
artery disease but with known persistent AF. Figure 3A shows the 
daily AF burden extracted from Holter monitoring. At baseline, 
the patient was in uninterrupted, persistent AF. Figure 3B is a 12 
lead ECG taken on the day of study initiation in order to confirm 
the presence of AF. After initiation of chloroquine treatment, 
AF burden was significantly reduced, with extensive periods of 
normal sinus rhythm, and the first conversion to normal sinus 
rhythm happened on the third day of treatment. Figure 3C shows 
Holter traces at baseline (top), immediately before treatment 
initiation (middle), where the patient was in AF, and during sinus 
rhythm on the third day of the oral chloroquine regimen (bottom). 
The patient did not have premature ventricular contractions 
while on chloroquine. The QT and QTc intervals while in AF, at 
the beginning of the study, were 418 ms and 428 ms respectively, 
and at the end of study, the QT and QTc intervals while in sinus 
FIgURe 2 | IKACh block with chloroquine. (A) Docking of chloroquine in the intracellular domain of Kir3.1. The lowest energy pose is shown. The D260 and F255 residues 
from each of the four Kir3.1 subunits are shown in green and orange sticks respectively. The tertiary amine nitrogen of chloroquine (cyan sticks) forms a hydrogen bond 
(black circle) with the side chain of D260 in the B subunit, while the aminoquinoline ring of chloroquine is in close proximity to the phenylalanine ring of F255 in the A 
subunit. Van der Waals representations of the channel bound to the drugs (cyan) viewed from the extracellular side is shown in the bottom panel. (B) Barium sensitive IKACh 
traces in response to −140mV step pulses from a holding potential of −20 mV in the presence of 1 μM chloroquine (CQ). (B) Concentration–response curves. IC50 for 
chloroquine block of IKACh: 1.2 μM, Hill Slope = −0.48, R2=0.74. (C) Top panel: Longitudinal view of chloroquine bound to Kir3.1. Orange box denotes the voxelated part 
of the channel shown below. Bottom panel: Voxelation of Kir3.1 ion permeation pathway (grey) in complex with chloroquine (cyan). A probe (magenta) of radius 2.2 Å or 
larger, is blocked by chloroquine.
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rhythm were 450 ms and 461 ms. After the chloroquine regimen 
was completed, and upon follow up, the patient was back in atrial 
fibrillation as documented by a 12 lead ECG.
effects of Chloroquine on Persistent AF in 
a 3D Model of human Atria
A model of persistent AF was initiated by ectopic activity in 
the right superior pulmonary vein, and the arrhythmia was 
maintained by two stable rotors located in the posterior wall of 
the left atrium, near the left superior pulmonary vein and in the 
superior vena cava (Figure 4A). The calculated EGMs at sites 
1, and 3, where the rotors were localized, showed double and 
fractionated potentials with low amplitude (Figure 4B). This 
occurred when the tip of the rotors pivoted at these locations, 
where the excitable but unexcited core resulted in multiple low 
amplitude deflections in the EGM. EGMs with single and double 
potentials were observed at sites 2 and 4 and were generated 
by wavefronts emanating from rotors and by wavebreaks at 
anatomical structures such as the crista terminalis and pectinate 
muscles. The DF was about 11 Hz (Figure 4B).
Chloroquine blocks IK1 and IKACh with a similar IC50 of about 
1 μM (0.97 μM for IK1 and 1.0 μM for IKACh), this is around the 
plasma concentration that is achieved in patients. Additionally, 
chloroquine blocks IKr with an IC50 of 2.5 μM. We thus tested if 
chloroquine block of either IK1, IKACh, IKr alone, or IK1 and IKACh 
together, or the three currents together terminates persistent 
AF. Figure 4C shows single cell left atrial action potentials when 
FIgURe 4 | Computational simulations of persistent AF in a 3D model of 
the human atria. (A) Snapshots of membrane voltage during persistent 
AF maintained by 2 rotors (curved arrows indicate rotation direction) in the 
posterior left atrium and the superior vena cava (SVC). Numbered dots 
indicate the locations of EGM recordings. (B) EGM traces displaying single 
(trace 2), double (traces 1 and 4) and fractionated (trace 3) potentials with 
low amplitude and high frequency of activation (DF of 11 Hz). (C) Single cell 
left atrial action potentials, at baseline AF (red trace), when IKr (blue dotted 
line), IK1 (blue solid line), IKACh (blue dashed line), IK1 and IKACh together (black 
dashed line), or the three currents together (black solid line) were blocked 
by 1 μM of chloroquine. LIPV, and LSPV: left inferior and superior pulmonary 
vein. RIPV, and RSPV: right inferior and superior pulmonary vein. SVC, and 
IVC: superior and inferior vena cava.
FIgURe 3 | Chloroquine effects on persistent AF. (A) Daily AF burden for 14 
days in Holter monitoring at baseline, and for 14 days upon initiation of oral 
chloroquine (amebiasis treatment regimen). (B) 12 lead ECG on the day of 
chloroquine initiation, confirming the presence of AF. (C) Holter ECG strips 
from baseline (top), right before treatment initiation (middle), and on the 3rd 
day of treatment when AF converted to sinus rhythm (bottom).
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chloroquine was applied at 1 μM in order to simulate ~50% block 
of the IK1 and IKACh currents and 30% block of IKr. When IKr was 
blocked by 30% (blue dotted line), APD90 prolonged from 98 ms 
(baseline AF, red line) to 101 ms, without changes in the RMP 
(−84.6 mV). When either IK1 or IKACh were blocked by ~50% (blue 
solid and blue dashed lines), APD90 prolonged to 133 ms and 118 
ms, with RMP values of −83.0 mV and −84.4 mV, respectively. 
When both IK1 and IKACh currents were blocked by ~50% (black 
dashed line), APD90 prolonged to 170 ms and the RMP slightly 
depolarized to −82.3 mV. When IK1, IKACh and IKr currents were 
blocked by 1 μM of chloroquine (black solid line), the RMP slightly 
depolarized to −82.3 mV, but the APD90 prolonged to 179 ms.
When we increased the chloroquine concentration to 2.5 μM 
in order to simulate ~70% block of the IK1 and IKACh currents and 
50% block of the IKr current, APD90 prolonged to 164 ms, 128 
ms and 103 ms, with RMP of −81.2 mV, −84.3 mV and −84.6 
mV, when IK1, or IKACh or IKr was blocked respectively. When 
both IK1 and IKACh were blocked by ~70%, APD90 prolonged to 
259 ms and the RMP depolarized to −78.6 mV. Finally, when the 
three currents were blocked by 2.5 μM of chloroquine, APD90 
prolonged to 291 ms, which corresponds to a 197% increase.
The two rotors maintaining AF at baseline continued to be 
present with up to 80% IK1 or 60% IKACh block. In such scenarios, 
the rotor located in the posterior wall of the left atrium near the left 
pulmonary vein drifted to the inferior wall and the rotor located 
in the superior vena cava migrated to the free wall of the right 
atrium. Up to 90% block of IKr did not change the dynamics of the 
two rotors maintaining AF at baseline. However, when the block 
of IK1 reached 90% (Figure 5A) or IKACh was blocked from 70 to 
90% (Figure 5B), persistent AF converted into a stable reentrant 
tachycardia located at the free wall of the right atrium. In both cases, 
the EGMs presented single potentials generated by the wavefront 
emanating from the reentry and only in the posterior wall of the 
left atrium where the rotor wavefront pivots, some double EGMs 
generated by the passage of the rotor’s core were observed in this 
area (Figures 5A, B). The DF was reduced to values between 8 Hz 
FIgURe 5 | Simulations of IK1, IKACh, or IKr block on persistent AF. (A) Snapshot of the single re-entry maintaining atrial tachycardia when IKACh was blocked by 70%, 
with the EGMs showing a DF of 8 Hz. (B) Snaphots of the single re-entry maintaining atrial tachycardia when IK1 was blocked by 90%, with the EGMs showing a DF 
of 9 Hz. (C) Snaphots of the 2 rotors maintaining AF when IKr was blocked by 90%, with the EGMs showing a DF of 11 Hz.
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and 9 Hz throughout the atria. Figure 5C shows that AF dynamics 
did not change appreciably when IKr was blocked by 90%.
When the effects of chloroquine on both IK1 and IKACh together 
were simulated, termination of persistent AF was achieved 
with ~50% block of IK1 and IKACh (Figure 6A). AF terminated 600 ms 
after the drug application, due to wavefront–wavetail interaction. 
Similarly, when the effects of chloroquine on the three currents 
together were simulated, termination of persistent AF was achieved 
with ~50% block of IK1 and IKACh and 30% block of IKr (Figure 6B). 
AF terminated 380 ms after the drug application. AF terminated 
earlier when higher concentrations of chloroquine were simulated.
DIsCUssION
Our results showed that the aminoquinoline chloroquine blocks IK1 
and IKAChV by binding a pocket in the Kir2.1 and Kir3.1 channels 
intracellular ion permeation pathways. Moreover, chloroquine 
significantly reduced the burden of persistent AF in an otherwise 
healthy female patient. This was likely due to the ability of the drug 
to prolong the action potential duration, leading to a slowing down 
of the arrhythmia’s dominant frequency, and subsequent failure of 
reentrant excitation due to wavefront–wavetail interaction.
Our molecular modeling suggested that chloroquine blocks 
IK1 and IKACh by binding to a pocket in the intracellular water filled 
vestibule of Kir2.1 and Kir3.1. The drug appeared to hydrogen 
bond with electronegative residue D260 in Kir3.1, and E224 in 
Kir2.1, in proximity to residue F255 in Kir3.1 and the equivalent 
Kir2.1 residue F254.
At baseline AF, our simulations showed EGMs with double 
and fractionated potentials with low amplitude and high 
frequency when the tip of the rotors pivoted on the recording 
points (pivot point). Experimental and clinical studies of AF 
have documented intracardiac polymorphic EGMs in high 
frequency areas with fibrillatory conduction (Ryu et al., 2006; 
Kalifa et al., 2006; Narayan and Krummen, 2012; Narayan et al., 
2012a; Narayan et al., 2012b; Narayan et al., 2012c; Narayan 
et al., 2012d) and fractionated EGMs when the rotor core passes 
at the recording point (Zlochiver et al., 2008). When IK1 or 
IKACh were individually blocked with increasing concentrations 
of chloroquine AF organized into reentrant atrial tachycardia 
due to APD prolongation. EGMs with single potentials in the 
atria were observed, characteristic of EGMs recorded during 
atrial tachycardias (Ryu et al., 2006). Double potentials were 
generated by the passage of the reentry core at the recording 
point in the free wall of the right atrium. It has been reported 
that atrial potentials consisting of two or more deflections 
can be recorded during atrial tachycardias in sites of earliest 
activation such as the crista terminalis (De Groot and Schalij, 
2006). When only IKr was blocked, AF dynamics did not change 
FIgURe 6 | Simulations of 1 μM chloroquine terminating AF by dual block of IK1 and IKACh by 50% (A), or by block of IKr by 30% and block of IK1 and IKACh by 50% 
(B). Voltage maps are snapshots of the last rotation of the re-entrant wave, where AF terminates after the wavefront interacts with the wavetail (white parallel lines). 
Curved white arrows: rotation direction. EGMs show arrhythmia termination.
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(Figure 5C) because IKr block had a minimal effect on the APD 
(Figure 4C). While it has been reported that chloroquine is an 
IKr blocker (Sanchez-Chapula et al., 2002; Traebert et al., 2004), 
and can prolong the QT interval (White, 2007; Stas et al., 2008), 
in our simulations IKr block did not contribute substantially to 
the atrial antiarrhythmic properties. This could be in part due 
to the lower expression of hERG channels in the atria compared 
to the ventricles (Pond et al., 2000). When both IK1 and IKACh 
(Figure 6A) or IK1, IKACh and IKr (Figure 6B) were blocked by 1 
μM chloroquine, AF terminated.
The oral chloroquine regimen which we administered to 
a patient with persistent AF consisted of 600 mg chloroquine 
base once daily, for 2 days, followed by 300 mg once daily for 12 
days. Therapeutic doses of chloroquine typically result in plasma 
concentrations around 1 µM (Karunajeewa et al., 2010), within 
the range of IC50 of IKACh and IK1 block by the drug. The cardiac 
safety of chloroquine when used correctly is well documented. 
For instance, from cardiac electrophysiological safety standpoint, 
chloroquine is safe. This was shown in a large cohort of patients 
with systemic lupus erythematosus who have been treated with 
chloroquine for an average of 8 years. Chloroquine was found 
to be not only electrophysiologically safe, but to also have 
antiarrhythmic activity in those patients with autoimmune 
disease (Wozniacka et al., 2006; Teixeira et al., 2014). Chloroquine 
poisoning occurs with ingestion of more than 5 g of chloroquine 
per dose (Riou et al., 1988).
Presently, the treatment of persistent AF remains inadequate 
(Rietbrock et al., 2008; Shukla and Curtis, 2014). Clinical studies 
demonstrated that antiarrhythmics, or ablation strategies do not 
result in complete freedom from AF, thus antiarrhythmic drug 
therapy remains an important line of defense. With currently 
used antiarrhythmics, the rate of conversion to sinus rhythms 
is not optimal (Zimetbaum, 2012). Additionally, toxicities 
including life threatening arrhythmogenesis are a significant 
risk in antiarrhythmic rhythm control pharmacotherapy. 
Nevertheless, pharmacological maintenance of sinus rhythm 
offers secondary end point benefits such as improvement in left 
ventricular function, walking distance, in addition to atrial size 
reduction (Chung et al., 2005; Hagens et al., 2005; Rienstra et al., 
2005). Hence, there is a need to improve the antiarrhythmic 
armamentarium, and to generate novel antiarrhythmics that 
are safe and that can reduce the burden of persistent AF or 
restore sinus rhythm. Based on this study and those of others, 
chloroquine appears to have antiarrhythmic properties in 
patients with AF (Burrell and Martinez, 1958; Harris et al., 
1988). On the other hand, chloroquine’s known side effects 
include QT prolongation (White, 2007; Stas et  al., 2008), and 
retinal and gastrointestinal adverse reactions (Al-Bari, 2015). 
Therefore, using rational design to discover novel inward 
rectifier blockers based on small aminoquinolines such as 
chloroquine, but with an improved safety profile, could offer 
new avenues in the search of new pharmacotherapies for AF.
The combination of 3D virtual models of atrial fibrillation 
with modeling of ion channel block by small molecules opens 
the door for the simulation of antiarrhythmic drug effects, 
leading the way for the development of a more effective and safer 
generation of anti AF agents.
lIMITATIONs
Atrial remodeling in persistent AF is complex, with many 
changes occurring from the transcriptional to post-translational 
levels (Anisimov and Boheler, 2003; Volkova et al., 2005). 
In addition, autonomic, anatomical, sarcolemmal, and 
subsarcolemmal electrophysiological remodeling has been 
described in persistent AF, resulting in slow and discontinuous 
electrical propagation, and aberrant excitation–contraction 
coupling, as well as increased perpetuation of AF (Kumar et al., 
2012). For instance, increased fibrosis (Koura et al., 2002), 
reduced ICaL, increased background inward rectifiers currents 
(IK1 and constitutively active IKACh) in addition to mitochondrial 
(Moslehi et al., 2012), and calcium handling abnormalities (Vest 
et al., 2005) are present in persistent AF. Such changes can play a 
significant role in creating the complex structural and functional 
substrates which promote the initiation and maintenance of 
high speed rotors responsible for atrial fibrillation. Therefore, it 
not unlikely that chloroquine’s effect is not exclusively due to the 
block of IKACh and IK1. At the therapeutic chloroquine plasma 
concentration, which is around 1 µM, the drug blocks about 
14% of the INa current, 7% of the ICaL, and 9% of IKs (Sanchez-
Chapula et al., 2001). It thus becomes conceivable that the multi-
target effect of chloroquine contributed to its antiarrhythmic 
properties in persistent AF.
Although the electrophysiological remodeling conditions 
that we used in our simulations can reproduce the action 
potential phenotype observed in patients with persistent 
AF, as mentioned above, they do not take into account 
the significant structural remodeling that is found in the 
chronically fibrillating atria, which increases the complexity 
of the arrhythmia. Additionally, our numerical results 
were obtained using a specific virtual atria model that lacks 
fibrosis, albeit it includes a great number of anatomical and 
morphological details including electrophysiology, anatomy, 
fiber direction, anisotropy, and heterogeneity. Although 
functional reentries and rotors have been widely reported as 
maintenance mechanisms of AF, future works must include 
structural remodeling in order to address how chloroquine 
may be antiarrhythmic when ionic and structural remodeling 
are the driving mechanisms of persistent AF.
The simulated results may be atrial cell model-dependent. 
For instance, other human atrial models show a more triangular 
action potential and have a flatter restitution curve, however, all 
models introduce ionic remodeling in a similar way, resulting 
in effects on the action potential that are similar to what our 
simulations suggest. These models generally include decreases in 
Ito, ICaL and IKur, and increased IK1. More recently, AF models that 
also account for the remodeling of intracellular Ca2+ handling 
have been developed (Grandi et al., 2011; Skibsbye et al., 2016; 
Colman et al., 2017; Bai et al., 2018). However, the simpler Ito/ ICaL/ 
IKur/ IK1 approach of persistent AF modeling remains commonly 
used, and we do not think that the use of a more complex model 
would substantially change the main results of our work. For 
modeling the effects of IKr block by chloroquine, we did not 
perform a concentration–response curve of the current block by 
the drug. We relied instead on the  literature reported IC50 of 2.5 
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µM (Traebert et al., 2004), and thus, it is possible that variations 
around this value could affect the simulation results.
Two studies have reported that a benzopyrene derivative 
(Podd et al., 2016) and a benzamide related compound 
(Walfridsson et al., 2015) selectively inhibited IKACh. However, 
the drugs failed in patients with paroxysmal AF and atrial 
flutter (Walfridsson et al., 2015; Podd et al., 2016). This could be 
because IKACh is not constitutively active in paroxysmal AF (Voigt 
et al., 2007) and mechanistically, atrial flutter is very different 
from AF (Olshansky, 2004). Consequently, inhibiting IKACh as 
part of an antiarrhythmic pharmaco-strategy should be reserved 
for the patient population in which the current is known to 
play a role. On the other hand, it is possible that chloroquine 
would reduce the burden of paroxysmal AF. It was shown that 
in patients with paroxysmal AF, a left/ right atrial gradient in 
IK1 exists (Voigt et al., 2010). This gradient could contribute to 
the ionic mechanism of paroxysmal AF, and therefore block of 
IK1 by chloroquine might be antiarrhythmic. Chloroquine might 
have limited antiarrhythmic effects in atrial flutter since its 
mechanisms are distinct from those of AF (Olshansky, 2004).
This is a proof of concept study which showed that chloroquine 
reduced persistent AF burden in a single patient. IK1 and IKACh 
block is proposed as a plausible mechanism for this reduction 
as suggested by the numerical simulations. Further studies are 
needed in order to demonstrate a relation between IKACh and IK1 
block and reduction of persistent AF burden.
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